Aethlon Medical Engages Maxim for Strategic Review, Finishes 2nd Trial Cohort
Aethlon Medical has engaged Maxim Group LLC to explore partnerships, mergers, and acquisition opportunities following inbound interest. The company also completed the second cohort of its Australian oncology trial, and safety data will now be reviewed by an independent Data Safety Monitoring Board.
1. Engagement of Maxim Group LLC
Aethlon Medical has appointed Maxim Group LLC as its exclusive financial advisor to evaluate a range of potential strategic transactions, including partnerships, mergers, acquisitions and other opportunities. This move follows preliminary inbound interest and aims to identify options that could enhance shareholder value.
2. Progress in Australian Oncology Trial
The company has completed enrollment of the second cohort in its Australian phase of the Hemopurifier oncology trial. Safety data from these additional patients will be submitted to an independent Data Safety Monitoring Board for review to inform future development steps.
3. Strategic Review Process Details
No definitive timeline has been set for the strategic review, and there is no assurance that any transaction will result. The board will pursue only those opportunities deemed appropriate for the company and its shareholders as it assesses the potential paths forward.